BAT CEO Denies Moving Listing to New York

BAT by 2FIRSTS.ai
Mar.18.2024
BAT CEO Denies Moving Listing to New York
British American Tobacco CEO Tadeu Marroco denies plans to move the company's listing from London to New York.

According to a report from the UK's Financial Times, Tadeu Marroco, the CEO of British American Tobacco, has denied the idea of moving the company's listing from London to New York, calling it a "distraction." Previously, the top ten shareholders who were pushing for this change have sold their stakes in the tobacco company.

 

Maroko told the Financial Times that the change of listing venue "will cause a lot of disruption internally," and he is "uncertain if its benefits are as obvious as some people suggest.

 

Last year, Rajiv Jain, Chairman and Chief Investment Officer of the US investment group GQG Partners with $105 billion in assets, urged British American Tobacco to switch its primary listing and clashed with management over the decision to suspend the company's stock buyback program.

 

According to two sources familiar with the matter, GQG sold its 4% stake in British American Tobacco last July because they refused to move and leverage the larger pool of capital in the US, particularly in tobacco stocks. In Europe, an investment environment dominated by ESG considerations means that almost no capital is willing to invest in the tobacco industry.

 

When asked whether he would consider changing the listing location during his tenure, Maroko said, "I believe we should not focus on this issue during this period.

 

He added that there are "many other things" he needs to do, including income in the United States and new products. "There is no indication that... going to the United States is a certainty."

 

He acknowledged that the London capital market is working hard to attract and retain listed companies, but he mentioned the advantages of staying in the UK for investors. Companies that have already moved their main listing venues to the United States include building materials group CRH, packaging company Smurfit Kappa, and gambling group Flutter.

 

Marroco stated, "If you hold shares in a British (listed) company and are overseas, you do not have to pay withholding tax on dividends, unlike in the United States."

 

He said, "I hope that within 10 years, we no longer have to have these discussions." "The reason why there is such a high level of emotions today is due to the frustration caused by some people leaving."

 

For investors, the main reason they are attracted to invest in tobacco stocks is the capital return from dividends and stock buybacks. One of the biggest active investors in British American Tobacco is Spring Mountain Investments, which is an investment vehicle of Kenneth Dart, a billionaire from the Cayman Islands and one of the world's largest foam cup manufacturers.

 

British American Tobacco announced this month that it will use the proceeds from the sale of a portion of its shares in Indian conglomerate ITC for £1.7 billion to restart its stock buyback program, starting with a £700 million buyback this year.

 

Marroco stated, "For me, the most important thing is the restart of repurchases, which should be a consistent feature of our capital allocation."

 

British American Tobacco is facing challenges in reversing the decline in tobacco sales in the United States, its largest market. This is due to people turning to cheaper brands and alternative tobacco products, in which the company is lagging behind the highly successful PMI, whose IQOS heated tobacco product has been very successful.

 

British American Tobacco's goal is to have 50% of its revenue come from alternative products by 2035, such as its Vuse e-cigarette and Glo heated tobacco devices.

 

Marroco acknowledged that English-American Tobacco "started late in the heated tobacco products field," but he stated that due to the company's market share in the US, they have the ability to catch up. "We have a large business in the US that can be used to sell (new products)."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
British American Tobacco's Japanese subsidiary, BAT Japan, launched VELO Mango Ice Medium on November 2, 2026, with distribution expanding to selected 7-Eleven, FamilyMart, NewDays and Seicomart stores from November 3. The new oral tobacco product contains 15 pouches per can and retails for ¥380, featuring a mango and cooling flavor profile at Medium intensity. At the same time, BAT Japan raised prices on multiple existing VELO products from ¥360 to ¥380 per can and withdrew selected SKUs from convenience store distribution without discontinuing them entirely. The changes affect product assortment, pricing and retail channel allocation.
product
Nov.04
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09